Antiviral therapy of hepatitis C with 1 genotype after liver transplantation-Reference-Cited by-同舟云学术

Antiviral therapy of hepatitis C with 1 genotype after liver transplantation

Published:2018-09-17 Issue:3 Volume:20 Page:105-115
ISSN:2412-6160
Container-title:Russian Journal of Transplantology and Artificial Organs
language:
Short-container-title:RJTAO

Author:

Tsiroulnikova O. M.¹,Umrik D. V.²

Affiliation:

1. V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)

2. V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation

Abstract

Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in all patients with persistent replication of the virus. Against the background of the necessary immunosuppressive therapy, the progression of the disease accelerates, leading to rapid decompensation of the liver. Antiviral therapy significantly improves the results of transplantation, but the use of standard interferon-based regimens is associated with low efficacy (no more than 30% for the most common 1 genotype of the virus) and poor tolerance. The article describes new interferon- free oral regimens used to treat the recurrence of HCV infection of 1 genotype.

Publisher

V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs

Subject

Transplantation,Immunology and Allergy

Reference64 articles.

1. Vsemirnaya organizatsiya zdravookhraneniya [Internet]. Informatsionnyi byulleten'. Gepatit S; 2 oktyabrya 2017 g. Vsemirnaya organizaciya zdravoohraneniya [Internet]. Informacionnyj byulleten’. Gepatit C; 2 oktyabrya 2017 g. http://www.who.int/ru/news-room/factsheets/detail/hepatitis-c.

2. Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J. Clin. Transl. Hepatol. 2014; 2: 124–133.

3. Hedskog C, Bhardwaj N, Chang S, Parhy B, Martin R, Zeuzem S et al. Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens. Reported by Jules Levin. AASLD: The Liver Meeting® 2017, October 20–24, 2017, Washington, DC.

4. Simmonds P, Becher P, Collett M et al. Family Flaviviridae In: Virus Taxonomy: Ninth report of the International Committee on taxonomy of viruses. Elsevier Science. 2011: 1003–1020.

5. Orlov ST, Neverov AD, Mikhailovskaya GV. Razrabotka i aprobatsiya test-sistemy «AmpliSens HCV-genotip FRT» na klinicheskom materiale i kontrol'nykh panelyakh QCMD. Sbornik trudov 6-i Vserossiiskoi NPK s mezhdunarodnym uchastiem «Molekulyarnaya diagnostika-2007». 2007; 1: 320–323. Orlov ST, Neverov AD, Mihajlovskaya GV. Razrabotka i aprobaciya test-sistemy «AmpliSens HCV-genotip FRT» na klinicheskom materiale i kontrol’nyh panelyah QCMD. Sbornik trudov 6-j Vserossijskoj NPK s mezhdunarodnym uchastiem «Molekulyarnaya diagnostika-2007». 2007; 1: 320–323.